A5057247480- PARP inhibition in cancer therapy
- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Cancer Risks and Factors
- Ultrasound and Hyperthermia Applications
- Urological Disorders and Treatments
- Radiopharmaceutical Chemistry and Applications
- FOXO transcription factor regulation
- Cancer Treatment and Pharmacology
- Radiomics and Machine Learning in Medical Imaging
- Endometrial and Cervical Cancer Treatments
- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- Molecular Biology Techniques and Applications
- GDF15 and Related Biomarkers
- Sexual Differentiation and Disorders
- Advanced Breast Cancer Therapies
- Mechanisms of cancer metastasis
- Cancer-related Molecular Pathways
National Institutes of Health
2025
University Hospitals Cleveland Medical Center
2025
Case Western Reserve University
2025
University School
2025
National Cancer Institute
2024
Bundeswehrkrankenhaus
1987
Cell phenotype underlies prostate cancer presentation and treatment resistance can be regulated by epigenomic features. However, the osteotropic tendency of limits access to metastatic tissue, meaning most prior insights into chromatin biology are from preclinical models that do not fully represent disease complexity. Noninvasive immunoprecipitation histones in plasma cell-free humans may enable capture disparate phenotypes. Here, we analyzed activating promoter- enhancer-associated H3K4me2...
<div>Abstract<p>Cell phenotype underlies prostate cancer presentation and treatment resistance can be regulated by epigenomic features. However, the osteotropic tendency of limits access to metastatic tissue, meaning most prior insights into chromatin biology are from preclinical models that do not fully represent disease complexity. Noninvasive immunoprecipitation histones in plasma cell–free DNA (cfDNA) humans may enable capture disparate phenotypes. In this study, we analyzed...
<p>Supplementary Figures 1-12 with embedded captions.</p>
<p>Supplementary Figures 1-12 with embedded captions.</p>
Triple-negative breast cancer (TNBC) is the subtype with poorest prognosis and lacks actionable molecular targets for treatment. Maternal embryonic leucine zipper kinase (MELK) highly expressed in TNBC has been implicated poor clinical outcomes, though its mechanistic role aggressive biology of poorly understood. Here, we demonstrate a MELK progression metastasis. Analysis publicly available datasets revealed that high expression correlates worse overall survival, recurrence-free distant...
Background: Due to the lack of molecular-targeted therapies for triple-negative breast cancer (TNBC), there have been efforts use multimodal strategies enhance efficacy existing such as radiation. The androgen receptor (AR) has identified a radiosensitizing target and is expressed in 25-50% TNBC tumors. combination AR inhibitors, enzalutamide (enza), radiation therapy (RT), leads radiosensitization AR+ models but mechanism by which mediates radioresistance not known, targeting this could...
Abstract Background: Breast cancer (BC), the most common globally and a leading cause of death in women, often utilizes radiation therapy (RT) as part treatment, with over 85% patients receiving RT after breast-conserving surgery. Still, 15% women experience local recurrence despite RT, underscoring need to better understand molecular mechanisms driving response resistance. We hypothesized that transcriptomic changes occur ionizing intrinsically radiosensitive resistant BC models would offer...